$BLMH.c couldn't be more undervalued. Bloom Health Partners (CSE: BLMH) is one company I’ve been watching lately whose SP does not seem to be reflective of its performance and growth in any way whatsoever.
Q2 revenue for the company was $11.1 million, which eclipses its current MCAP of $7.61 million. Bloom has stated guidance of $25-$28 million in revenue for 2022, which it is well on track to meet. If the company is able to achieve its yearly guidance, that will put the company’s earnings at roughly 4x its valuation.
In short, this company is shockingly undervalued based on the fundamentals. On top of this, it has shown accelerated growth in the first two quarters of this year, and is planning to continue this acceleration.
This is going to be a big one to keep an eye on, especially once we begin to see a recovery in the markets at large.
$BLMH.c is currently trading at $.195.
https://ceo.ca/@newsfile/bloom-health-partners-reports-profitable-fiscal-q2